307 related articles for article (PubMed ID: 31182917)
1. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
Shao N; Shi Y; Yu L; Ye R; Shan Z; Zhang Z; Zhang Y; Lin Y
Int J Biol Sci; 2019; 15(5):962-972. PubMed ID: 31182917
[TBL] [Abstract][Full Text] [Related]
2. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
3. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
4. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
7. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
9. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
11. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
12. Integrating PARP inhibitors into the management of breast cancer: where are we?
Azim HA; Kassem L; Azim H
Chin Clin Oncol; 2021 Jan; 10(5):50. PubMed ID: 33440946
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
15. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
16. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
17. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
Chen Z; Wang X; Li X; Zhou Y; Chen K
J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
[TBL] [Abstract][Full Text] [Related]
18. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
[TBL] [Abstract][Full Text] [Related]
20. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
